Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Technology evaluation: G-3139.

D Banerjee1

  • 1Memorial Sloan Kettering Cancer Center, New York, NY, 10021 USA. banerjed@aol.com

Current Opinion in Molecular Therapeutics
|November 21, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Yttrium-88 glass microsphere: A potential radiotracer for radioactive particle tracking applications.

Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine·2026
Same author

Does active case finding detect TB early in programme settings? A national-level study in India.

Public health action·2026
Same author

Axisymmetric Eigenmodes Excited by Alpha Particle Energy Gradients in JET D-T Plasmas.

Physical review letters·2026
Same author

Insights into the Chemical Durability and Structure of ZnO-Incorporated Sodium Borosilicate Glasses from Solid-State NMR.

The journal of physical chemistry. B·2025
Same author

Neutrophil-lymphocyte ratio as an early predictive biomarker for severity in patients with high altitude pulmonary edema.

Medical journal, Armed Forces India·2025
Same author

Fabry disease in the haemodialysis population: outcome of a UK screening study (SoFAH).

BMC nephrology·2025
Same journal

Gene therapy: Have the risks associated with viral vectors been solved?

Current opinion in molecular therapeutics·2011
Same journal

Teduglutide, a glucagon-like peptide-2 analog for the treatment of gastrointestinal diseases, including short bowel syndrome.

Current opinion in molecular therapeutics·2010
Same journal

Dulaglutide, a long-acting GLP-1 analog fused with an Fc antibody fragment for the potential treatment of type 2 diabetes.

Current opinion in molecular therapeutics·2010
Same journal

Corticorelin, a synthetic human corticotropin-releasing factor analog, for the treatment of peritumoral brain edema.

Current opinion in molecular therapeutics·2010
Same journal

Mogamulizumab, a humanized mAb against C-C chemokine receptor 4 for the potential treatment of T-cell lymphomas and asthma.

Current opinion in molecular therapeutics·2010
Same journal

Gevokizumab, an anti-IL-1β mAb for the potential treatment of type 1 and 2 diabetes, rheumatoid arthritis and cardiovascular disease.

Current opinion in molecular therapeutics·2010
See all related articles

G-3139, an antisense drug targeting bcl-2, shows promise in early cancer trials with minimal side effects. Further studies are ongoing for various cancers, including lymphoma and prostate cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • G-3139 is an antisense phosphorothioate oligodeoxynucleotide (AS PS ON) developed by Genta Inc.
  • It functions by suppressing bcl-2 expression, a target relevant to various cancers.
  • The drug is currently undergoing Phase I/IIa clinical trials for multiple cancer types.

Purpose of the Study:

  • To evaluate the safety and efficacy of G-3139 in cancer patients.
  • To explore G-3139's potential in combination therapies for various malignancies.
  • To assess dose-escalating effects and potential drug activity in specific cancer types.

Main Methods:

  • Phase I/IIa dose-escalating trials were conducted.
  • G-3139 was administered in conjunction with other chemotherapeutic agents (e.g., docetaxel, mitoxantrone, cyclophosphamide, dacarbazine).

Related Experiment Videos

  • Studies included patients with non-Hodgkin's lymphoma, prostate cancer, malignant melanoma, colorectal cancer, small cell lung cancer, and leukemia.

    • Main Results:

    • In a Phase I/IIa trial for non-Hodgkin's lymphoma, no serious drug-attributable adverse effects were observed.
    • Encouraging signs of potential drug activity were noted, including cancer mass reduction and a complete response lasting over 38 weeks in some patients.
    • Ongoing trials are investigating G-3139 in combination with standard chemotherapies for relapsed NHL and other advanced cancers.

    Conclusions:

    • G-3139 demonstrates a favorable safety profile in early-phase trials.
    • The drug shows potential for therapeutic activity, particularly in combination regimens.
    • Further clinical development is warranted to establish G-3139's efficacy across a range of cancers.